On June 3, Abivax S.A. rose 16.03% in regular trading, trading at approximately $83.95/share, with trading volume of $145 million. The stock is experiencing a sharp intraday rebound following a more than 40% collapse in the prior session.

The bounce reflects selective dip-buying after the company's Phase 3 maintenance trial (ABTECT) for obefazimod in moderately to severely active ulcerative colitis met its primary endpoint but was overshadowed by safety concerns. Three malignancy cases — prostate cancer, breast cancer, and colonic dysplasia — were reported in the 50 mg dose group. Although investigators deemed the cases unrelated to the drug, Wedbush Securities noted an increased risk of a black box warning, and Jefferies analysts stated that cancer-related adverse events would continue to suppress market sentiment and the drug's commercialization prospects.

Despite the rebound, safety controversy remains unresolved. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating. The NDA submission timeline has been pushed to Q4, later than some market expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)